Centre for Biosimilars reports that COVID-19 could catalyse biosimilar uptake in US

Apr 23, 2020

On 23 April 2020, the Centre for Biosimilars reported that COVID-19 could speed up biosimilar uptake in the US. Factors which may influence this include widespread unemployment (lack of health insurance to pay for costly originator products), faster adoption of bills that support biosimilar uptake, and potential health care payment model changes.

Print Page Mail Article